period. I quarter, good Camilla, you, And Thank Frank from will questions. the then highlights financial and everyone. Today, and and provide execution then highlights will you strategy for your take us. will you joining the for we take Thank through afternoon,
thank growth of that We $XX.X XXXX. our revenue, strategy to of by patient combined innovative that As saw total growth Melanoma and grew significant of and the quarter our employees which mission XX% our to through diagnostic comprehensive we first work with Castle strong first core our of of which operational volume We and the offering health million XXXX DecisionDx-Melanoma XX% over in all for always, I our year-over-year in to We during continued the want provide quarter, momentum strong and care. their continued a us of almost and our tests had is focus attribute quarter dedication will DiffDx-Melanoma, believe test delivered test performance. quarter in we strong volume and which business dermatology year. myPath dermatology over for DecisionDx-SCC improving the hard on our guide rest the
continue by expression pillars, profile or the possible But starting in with with initiatives in-market entered our investments an make made in for strong the launches growth. in investments business pillars April emphasize that with under of estimated I the of delivered. dermatology addressable XX% have to approximately grew we in-market million. $X maintaining across further would our XXXX, to each headwind strategy, I we X just compared reports billion. U.S. total with the our second test TAM Despite of with flagship $XXX to of XXXX DecisionDx-SCC our test the XXXX, entered of we strategic estimated our and our U.S. as under gene X to billion, first DecisionDx-Melanoma, $X core accelerate test, of market, first first, our growth the dermatology our as TAM, of XXXX, following XXXX pillars reports business. acquisition of Test quarter well X,XXX in intended core growth an focus of careful quarter We AltheaDx, by just U.S. on of highlight half And in-market DiffDx-Melanoma TAM now of COVID estimated like opportunities. other as and pipeline will these both an
melanoma As XXXX diagnosis of we 'XX of during impacts data. our COVID-XX cutaneous have the according analysis discussed, third-party and to
trending in pre-COVID continue back are to that levels. to data ways not the see We
these However, considering now trends we normal. are X a new years later,
anyway. now, For
despite related success by driven our We we will diagnoses, believe dermatology for initiatives. reduce headwinds position have we and and these our franchise growth that execution on resiliency is in decisions made strengthen strong believe to growth our business our potential
in XXXX the we to dermatology-facing it where instance, representatives doubled now. For our stands mid-XXs,
active the so representative to that would promotional communicated XXXX, XXXX, our decision of advantage half July we we As XXXX the commercial see first market. we to you a this in that double team could responsiveness of take dermatology-facing with we by that made enter the in
seen about good have the we so So momentum XXXX. in far we strong feel
discussed, territories. will team of of assess we to we As the number outside commercial a our continue size and sales
inside our medical affairs, of outside -- sales adjust of sales investments and territories, Our include our based mix marketing assessments evaluation evaluations. and we'll support, these upon will
earlier, As believe I that promotionally market our responsive. is we noted
we So programs, of include us of schedule in federal the R&D, extended our which for dermatologic position our contract all recently investments sales should a our suite with for efforts, the tests skin expansion interface cancer was across anticipate system, dermatology and medicine peer-to-peer XXXX. force record modernizing with VA, well our growth tests to our system that medical of remainder and our leading supply electronic our
of clinical the follow-up addition SEER to Cancer patients only plan. and to Institute National the had real-world pathological survival with This data the data in expanded determine who who was improved collaboration the their compared highlight dermatology to patients our benefit traditional significant presentation access treatment for to expanded of have program. Another untested factors DecisionDx-Melanoma test, pathologic and clinical traditional and showed
Specifically, patients test DecisionDx-Melanoma patients. improvement diagnosed compared to survival who with a melanoma-specific the had untested and received in melanoma XX%
had DecisionDx-Melanoma addition this Switching melanoma-specific me survival. have factors, to as controlling Let patients clinical pathologic is factors factors results to in well to in now of number benefit pathologic restate it who a clinical having test as DecisionDx-SCC. important the When and and socioeconomic improvement XX% clinically.
remain timing time, on uncertain have discussed for this potential We timing. coverage test. Medicare of At we this
to for we mid-XXXX. plan continue Medicare prior coverage However, to
will test out submitted review quarter. to MolDX recall in that second for You was this the dossier to technical for the come
We as do. to offer patients is continue it this expect to right to the test believe we thing to
to continue we expect continues payers as per and department to to build payments process, some our billing Our in XXXX. receive
revolutionizing the expression currently assess Now our disease a for data last inflammatory gene Dermatitis pipeline test our Conference turning development concluded scraping to RNA to that skin presented initiatives. pipeline at which skin Atopic technique produced proof-of-concept therapy month, to response. noninvasive predict reproducible that's in XXXX We sufficient
identified Specifically, and our data fees interest. portion development the study of ongoing of preliminary in proof-of-concept validation
and strong in demonstrated accordance for skin-scraping Importantly, a study technique. interoperative reliability technical
confident we our sampling So noninvasive feel about skin approach.
validation prospective estimated recall, you validate our which and a test. end XXXX, initial patients an to and XXXX, initiated U.S. believe to clinical to approximately have launch we data develop development expect $X.X would on As TAM. we add study this the pipeline by are test this in of We and to multi-center billion pipeline track in may X,XXX we XXXX,
discuss recent conditions. acquisition our As we pillar, opportunities, are to and strategic excited as of we PGx growth progress ongoing our well IDgenetix our the last mental move of pharmacogenomic to health as integration, for the cycle tissue test
to I As laboratories approximately in-market above, billion. these $X expanded X approximately estimated mentioned now TAM the our U.S. billion $X acquisition by of
and we Medicare we mentioned value into clear and in addressed have franchises X made already enable acquisitions our creation we unmet as these on that reimbursement markets commercialized long-term As believe well us opportunities existing a and to gained strategic coverage, products complementary commercial build select objectives. as with need past further clinical have calls, growth
midterm, For strategic the X franchise health from the conditions. near and markets: we mental gastroenterology and of opportunities other focus of will position building assessment dermatology, our
XXXX. is TissueCypher granted our diagnostic status during the importance it obtained provide that status of the called XX-day to the clinical test marketization side the is other reception half in As we that criteria. rule, we test diagnostic tests identified first laboratory simplifies seen test information from or the other laboratory requires for have new the test. among tissue TissueCypher any exempts clinicians for CMS fact combination status, Esophagus test, advanced billing what business be patients. significant from relates Medicare ADLT quarter, In Barrett's diagnostic ADLT positive cannot that that from clinical second ADLT, our which a Of of or process the
Barrett's was alone, first previously recognized Clinical management informed pathology esophageal significantly Dr. and pooled Mayo from reinforces the dysplasia in article and Esophagus. the ability and The based with of or peer-reviewed in diagnosis X Hepatology studies allowing to clinical more validation occur. predictions published patients to in quarter TissueCypher for the of Barrett's The management Journal. analysis cancer these an Iyer, predictions XXX on by independent the high-grade patients study a the Esophagus analysis published of Esophagus progression announced improve also compared Clinic We variables decisions clinical expert the Prasad Barrett's a of in to to Gastroenterology the led of
as instance, factors non-dysplastic concerning XXX,XXX predictors of TissueCypher. represent for the we X For progression known is on pathologic that intended clinical endoscopies particularly of analysis patient combination believe This approximately impact patients XX% or TissueCypher are per the group use they disease. approximately and with in Barrett's Esophagus in evaluated market year with
have continue turnaround facilitate We enhancements, Pittsburgh on signed TissueCypher, for laboratory test make we lease to optimizing includes time. our new which our progress progress and to further
You expect to the what determine but team, appropriate XX outside Similar continue based our we'd commercial like, in the response, initial recall well research provider may sales will expansion territories. our our response consists commercial territories. the add quarter, dermatology XX to we third look market as and approximately market commercial XX outside to sales sales to team of upon assess will XX approximately additional with sometime to territories initial as XX outside ending year
aims proprietary clinical Let's closure X same we turn reiterate our our diagnosing the in with to by limit our through this strategic commercial investment. the states subsequent unmet diagnosing we acquisition recent high-value focus. strategic the Number the is transform with late focus this same in on the And clinical or decision now identify well high accomplished we our treating decision patient the points Number three, clinician management IDgenetix how point clinical We providing we, April. served to clinician. on where AltheaDx current I treating test multiple actual and clinician clinical customer want that Castle features. thereby information aligns are number one, four, basis, focus investment disease my main decision within points believe to poorly factors. aligns by high-value at to disease needs. acquisition providing and two, to IDgenetix Number products. leveraging We and this our focus. or states tests subjective of
from recall major for in depression. may previously with use April X Medicare had you as our diagnosed only coverage patients Additionally, announcement, IDgenetix
total mental to a territories improvement with health test into As the additional the randomized for in those joined the IDgenetix pharmacogenomic team AltheaDx family. showed enter includes a depression multi-gene who May, patients approximately reminder, patients had of other controlled Medicare choice commercial a conditions a X. IDgenetix now knowledge information. greater And assessed sales without received outside with all as coverage XX that who test we the X.Xx covering were trial X than to compared Castle and showed remission physician's a diagnosed
Mental the Camille are We of Schrier, the announced And Ms. in help from the will I updated updating treatment to mental about call promote results Health Frank, on the with IDgenetix over details IDgenetix you mental Month We near XXXX relating to revenue to provide from look excited potential testing now with test patients forward XXXX financial to our help America to IDgenetix. in term health potential turn our Awareness conditions. health has we will collaboration diagnosed the a in recently progress genetic improve and to conditions. who and guidance.
